Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® ...

Cambridge, UK-based biotech start-up Maxion Therapeutics, which is developing antibody-based KnotBody drugs for ion channel- ...

Cambridge biotech Maxion Therapeutics has raised $72 million (£58m) in a Series A financing to further grow the business ...

The partnership brings together Salipro’s tech for stabilising drug targets from Boehringer’s drug discovery programmes.

Myrobalan Therapeutics, a biotechnology company developing potent, selective, and brain-penetrant oral small-molecule therapies to restore brain function, today announced a grant of over $850,000 from ...

Researchers at Monash University have uncovered how the gut—and the food we eat—affects high blood pressure. Their discovery ...

This study makes the fundamental discovery of the first natural animal rhodopsin that uses a chloride ion instead of an amino acid side chain as a counterion. Using a combination of biochemical and ...

Endocannabinoids are lipid mediators that interact with G protein-coupled receptors, including cannabinoid CB2 receptor (CB2R), which is mainly expressed in peripheral tissues with immune functions.

Each cell in your body relies on precise communication with other cells to function properly. At the center of this process ...

Urcosmid is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune ...

Fast track was first introduced by FDA to expedite development and review of drugs to treat serious conditions lacking any FDA-approved drug,” commented Gary S. Jacob, Ph.D., Chief Executive Officer ...